The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. In June 2026, shareholders approved a major capital increase and flexible share consolidation framework, with the company implementing a 1-for-31 share consolidation to maintain Nasdaq listing. The company faces scaling challenges typical of China-focused digital health platforms.
Cyborg Score Rationale
Zhongchao operates in a growing Chinese healthcare digital market with established partnerships (Johnson & Johnson since 2017), but faces significant headwinds: microcap scale with limited financial disclosures, aggressive dilutive capital raises (June 2026), multiple share consolidations, and structural regulatory exposure to China operations. Strategic positioning in medical education and patient services is defensible but execution risk is elevated.
Top Insights
Company underwent 1-for-31 share consolidation (June 2026) to maintain Nasdaq compliance, signaling stock price pressures and potential delisting risk amid microcap trading volumes and limited institutional support.
MDMOOC platform serves Chinese healthcare professionals through clinical training, case studies, continuing education, and medical content; partnerships with J&J (since 2017) and China Association of Health provide revenue diversification and credibility.
Dual revenue model (MDMOOC services plus pharmaceutical sales) creates operational complexity; limited recent financial disclosures (trading below $2/share as of July 2026) suggest scale and profitability challenges in execution.
Named Competitors
Medpeer — Healthcare professional network and medical education platform in China
Guokr — Medical science knowledge platform serving healthcare professionals and patients
Chunyu Doctor — Online healthcare services and professional medical consultation platform in China
39.net — Digital health information and healthcare professional education platform in China
Recent Developments
(June 2026) Zhongchao shareholders approved major capital increase and flexible share consolidation framework
(June 2026) Company implemented 1-for-31 share consolidation to maintain Nasdaq listing
(May 2026) Zhongchao announced platform-based services expansion for cancer and rare disease patients
Open the full interactive Zhongchao Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.